Among current studies are:

Effector cells in type I allergy: the role of mast cells and basophil granulocytes

Allergic symptoms have been monitored by clinical markers and may be dependent on interaction of the nervous and the immune systems. We develop markers for immunologic monitoring of allergic disease through basophil activation. This is used to monitor the effect of immunotherapy (Mikkelsen et al, 2010 PMID 20158902) and anti-IgE treatment on allergic disease such as basophil sensitivity in prospective trials using the basophil activation test. In addition, we explore the usefulness of more robust markers of allergic disease as proxy for these complex, fragile measurements.

We have developed an eight-week protocol to measure mature mast cells from CD133+ peripheral blood stem cells (Krohn 2013 PMID 23294195). We explore the in vivo counterpart of cultured mast cells in lung biopsies of asthmatics and controls in a collaborative study with national and international partners. These mast cells are used to investigate the relationship between IgE, FceRI and effector cell function under relevant physiological conditions.

Ongoing studies include a study on biomarkers and their relation to clinical outcomes in allergic patients treated with subcutaneous immunotherapy and a study investigating the clinical effect and paraclinical changes in allergic patients treated with ultrasound-guided intralymphatic immunotherapy.


Hans Jürgen Hoffmann, professor, PhD,
Johannes Schmid, consultant, MD,Consultant, Associate Professor, Specialist in Respiratory Medicine,
Tina Skjold, consultant, MD, PhD,